A Phase 3 interventional study of Icatibant and Placebo in Angiotensin Converting Enzyme Inhibitor Induced Angioedema, sponsored by Shire. Completed at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Angioedema with a site in United States — 8 open to participants now, 10 under way, 4 of them phase 3. Angioedema · United States.
Among the 32 studies in Angioedema with a site in United States, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2013, is one of 9 in phase 3, and was the 11th registered.
69 studies on the registry are indexed under Angioedema; 16 are open to participants now.
Browse Angioedema studies →8 of the 32 studies in Angioedema with a site in United States are open now. Recruiting first, the newest first:
Pharvaris Netherlands B.V. · Sites in United States, Australia, Austria and 13 more countries
Ages 18+
CSL Behring · Sites in United States, Austria, Canada and 2 more countries
Ages 12+
Institute for Asthma and Allergy · Sites in United States
Ages 18–75
Bernstein Clinical Research Center · Sites in United States
Ages 18+
Octapharma · Sites in United States, Albania, Argentina and 11 more countries
Ages 2+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Angioedema studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 9 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 45 across 44 interventional studies indexed under Angioedema.
Median enrollment 49 across the 26 interventional studies, 200 across the 5 observational. Of the 20 that completed or were terminated, 16 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 8 studies filed under Angioedema — fewer than ten, so there is no comparison to draw.
6 of the studies in Angioedema with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
| NCT06361537Phase 3OctapharmaStudy of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks | 2026-12 |
| NCT07266805Phase 3Pharvaris Netherlands B.V.Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | 2027-06 |
| NCT05584488Columbia UniversityAllergy and Immunology Natural History Study | 2027-01 |
| NCT06210698Foundation For Rare Disease ResearchAngioedema Biomarker Research Study | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Angioedema with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to compare the safety and efficacy of icatibant with placebo in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults.
Angiotensin-converting enzyme inhibitors (ACE-Is) are the class of medications prescribed most frequently for the treatment of hypertension. They are also used post myocardial infarction as well as in patients with heart failure, diabetes mellitus, and chronic kidney disease. Approximately 35 to 40 million patients are on ACE-Is worldwide.
Study HGT-FIR-096 is a multicenter, Phase III, randomized, double-blind, two-armed, placebo-controlled trial. The study population will consist of 118 adult patients, 18 years of age or older, who present with an acute ACE-I-induced angioedema attack. The primary aim of the study is to demonstrate that icatibant is significantly more effective than placebo in resolving attacks of angioedema caused by ACE-I based on the Time to Meeting Discharge Criteria (TMDC). Safety and tolerability, as well as the pharmacokinetics (PK), of icatibant will also be evaluated. Eligible patients will be randomized at a 1:1 ratio to receive a single sub-cutaneous injection of either 30 mg icatibant or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patient has any of the following vascular conditions that, in the judgment of the investigator, would be a to participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
Drug: Icatibant
Placebo will be administered as a single subcutaneous injection
Drug: Placebo
Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
Also known as: Firazyr
Time to Meeting Discharge Criteria (TMDC)
TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.
Time frame: Day 0 up to Day 5
Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as adverse events/serious adverse events that started or worsened after the study drug treatment.
Time frame: From start of study drug administration (Day 0) up to follow-up (Day 5)
Number of Participants With Treatment Emergent Injection Site Reaction
Injection site reaction included erythema, swelling, cutaneous pain, burning sensation, itching and warm sensation
Time frame: Day 0 to Day 5
Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination
During laboratory evaluation, serum chemistry and hematology blood tests, and urinalysis were performed. Vital signs parameters included evaluation of pulse rate and systolic and diastolic blood pressure. Standard 12-lead ECGs were performed and ECG recordings were read locally at the study site by a cardiologist. Physical examination was performed with examination of major body systems per routine clinical practice.
Time frame: Day 0 to Day 5
Time to Onset of Symptom Relief (TOSR)
TOSR was calculated for the individual symptoms with pre-treatment scores of 2 (moderate) or more improved by at least 1 severity grade and the individual symptoms with pretreatment scores of 0 or 1 (absent or mild) were scored again at 0 or 1 and all the subsequent assessments continued to satisfy this condition. Time-to-event data were summarized using Kaplan-Meier estimates.
Time frame: Day 0 up to Day 5
Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema
Airway Intervention included intubation, tracheotomy, cricothyrotomy.
Time frame: Day 0 up to Day 5
Number of Participants Admitted to Hospital or Intensive Care Unit (ICU)
Number of participants with and without an occurrence of admission to the hospital (inpatient) or ICU post-treatment due to the ACE-I-induced angioedema attack were described.
Time frame: Day 0 up to Day 5
Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration
Number of participants with the use of conventional medications (corticosteroids, antihistamines, epinephrine) for the treatment of symptoms of the ACE-I- induced angioedema attack following study drug administration were presented.
Time frame: Day 0 up to Day 5
Percentage of Participants With Time to Meeting Discharge Criteria (TMDC) at Specified Time Points
TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.
Time frame: 4, 6, and 8 hours post treatment
Area Under the Plasma Concentration Versus Time Curve (AUC) of Icatibant and Its Metabolites (M1 and M2)
Area under the plasma concentration-time curve of Icatibant and its metabolites (M1 and M2) were analyzed. A population pharmacokinetic analysis approach using sparse pharmacokinetic sampling obtained from a subset of subjects was used to evaluate exposure to icatibant.
Time frame: 0.75 and 2 hours post-dose
The study was conducted at 59 sites in the United States, United Kingdom, Israel and Canada.
| Milestone | Icatibant 30 mg | Placebo |
|---|---|---|
| Started | 61 | 60 |
| Completed | 60 | 57 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other | 0 | 1 |
TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.
| days | Icatibant 30 mg | Placebo |
|---|---|---|
| Time to Meeting Discharge Criteria (TMDC) | 4.03 (2.03 to 6.00) | 4.00 (1.03 to 6.00) |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as adverse events/serious adverse events that started or worsened after the study drug treatment.
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Participants with TEAEs | 27 | 21 |
| Participants with TESAEs | 2 | 1 |
Injection site reaction included erythema, swelling, cutaneous pain, burning sensation, itching and warm sensation
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Erythema | 31 | 13 |
| Swelling | 17 | 13 |
| Cutaneous pain | 10 | 7 |
| Burning sensation | 15 | 7 |
| Itching | 13 | 6 |
| Warm sensation | 16 | 8 |
During laboratory evaluation, serum chemistry and hematology blood tests, and urinalysis were performed. Vital signs parameters included evaluation of pulse rate and systolic and diastolic blood pressure. Standard 12-lead ECGs were performed and ECG recordings were read locally at the study site by a cardiologist. Physical examination was performed with examination of major body systems per routine clinical practice.
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical Examination | 0 | 0 |
TOSR was calculated for the individual symptoms with pre-treatment scores of 2 (moderate) or more improved by at least 1 severity grade and the individual symptoms with pretreatment scores of 0 or 1 (absent or mild) were scored again at 0 or 1 and all the subsequent assessments continued to satisfy this condition. Time-to-event data were summarized using Kaplan-Meier estimates.
| days | Icatibant 30 mg | Placebo |
|---|---|---|
| Time to Onset of Symptom Relief (TOSR) | 2.00 (0.58 to 3.08) | 1.55 (0.50 to 3.88) |
Airway Intervention included intubation, tracheotomy, cricothyrotomy.
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Number of Participants Experienced Airway Intervention Due to ACE-I-induced Angioedema | 1 | 0 |
Number of participants with and without an occurrence of admission to the hospital (inpatient) or ICU post-treatment due to the ACE-I-induced angioedema attack were described.
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Number of Participants Admitted to Hospital or Intensive Care Unit (ICU) | 22 | 22 |
Number of participants with the use of conventional medications (corticosteroids, antihistamines, epinephrine) for the treatment of symptoms of the ACE-I- induced angioedema attack following study drug administration were presented.
| participants | Icatibant 30 mg | Placebo |
|---|---|---|
| Number of Participants Experienced ACE-I-induced Angioedema Attack Following Study Drug Administration | 35 | 35 |
TMDC was based on the investigator-assessed angioedema-associated upper airway symptom assessments. It was calculated from the time of study drug administration to the earliest time point at which the symptoms of difficulty breathing and difficulty swallowing were absent and the symptoms of voice change and tongue swelling were mild or absent and all subsequent assessments continued to satisfy these conditions. These symptoms were evaluated by the investigator using a 5-point grading scale (0=absent, 1=mild, 2=moderate, 3=severe, and 4=very severe). TMDC was analysed using Kaplan-Meier estimates.
| percentage of participants | Icatibant 30 mg | Placebo |
|---|---|---|
| At 4 hours post treatment | 55.0 | 60.3 |
| At 6 hours post treatment | 78.3 | 75.9 |
| At 8 hours post treatment | 91.7 | 91.4 |
Area under the plasma concentration-time curve of Icatibant and its metabolites (M1 and M2) were analyzed. A population pharmacokinetic analysis approach using sparse pharmacokinetic sampling obtained from a subset of subjects was used to evaluate exposure to icatibant.
| hours*nanogram per milliliter (h*ng/mL) | Icatibant 30 mg |
|---|---|
| Icatibant | 2530 ± 786 |
| Metabolite M1 | 2890 ± 813 |
| Metabolite M2 | 3180 ± 931 |
Collected over From start of study treatment up to Day 5. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Icatibant 30 mg | — | 2/60 (3.3%) | 14/60 (23.3%) |
| Placebo | — | 1/58 (1.7%) | 11/58 (19%) |
| Event | Icatibant 30 mg | Placebo |
|---|---|---|
| Rash pruriticSkin and subcutaneous tissue disorders | 0/60 | 1/58 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/60 | 0/58 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 1/60 | 0/58 |
| Event | Icatibant 30 mg | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 7/60 | 4/58 |
| AngioedemaSkin and subcutaneous tissue disorders | 7/60 | 2/58 |
| NauseaGastrointestinal disorders | 0/60 | 3/58 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/60 | 3/58 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 3/60 | 2/58 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Icatibant 30 mg | Placebo | Total |
|---|---|---|---|
| Mean | 60.9 ± 12.1 | 61.8 ± 13.4 | 61.4 ± 12.7 |
| Sex: Female, Male(Participants) | Icatibant 30 mg | Placebo | Total |
|---|---|---|---|
| Female | 27 | 35 | 62 |
| Male | 34 | 25 | 59 |
Ran from Dec 2013 to primary completion in Aug 2015, 20 months.
Results were first posted in Oct 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant